The BrainSafe II project builds upon a successful Research for the Benefit of SMEs project and will deliver an innovative technology for the autonomous, calibration free, non-invasive, rapid, accurate and precise absolute intracranial pressure (aICP) determination. The resultant device will exhibit absolute intracranial pressure measurement to within SD = ± 2,5 mmHg. The target time for the whole procedure is 9 minutes (compared with a current average 23 minutes). The device resulting from this research will be a very significant breakthrough in healthcare delivery. The timely application of the device in the diagnosis of TBI patients will save approximately 9,400 lives, reduce the number of permanently disabled citizens by 30,000 and increase the survival rates and lifespan for an additional 136,000 patients with TBI within the EU annually. The BrainSafe II concept is initiated by the SME Vittamed who has background knowledge and holds all background IPR of the proposed technological concept. The R&D will be completed by a consortium of experts within ultrasonic techniques, signal processing, microdrivers and ergonomic hardware design to ensure full safety and comfort to patients and ease of use and time saving for medical personnel. The RTOs are Kaunas University of Technology in Kaunas, Lithuania, Singer Instruments and Control Ltd. in Israel and Estonia Innovation Institute. The SME partners joining Vittamed form a coherent supply chain with the skills to manufacture and distribute the final product. The SMEs are Microplast, for high precision plastics moulding, Medelkom for its expertise with ultrasound transducers, Artec Design for electronic subsystems and Vittamed for signal processing software. Following, clinical trials, widespread adoption of the technology will lead to global sales of about €80million within a 5 year period post project, securing or creating 135 jobs within the EU.